Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.

Lily J Andrews Zak A Thornton Saanwalshah Samir SaincherIan Y YaoSarah DawsonLuke A McGuiness Hayley E JonesSarah JefferiesSusan C Short Hung-Yuan Cheng Alexandra McAleenan Julian P T Higgins Kathreena M Kurian

Published in: Neuro-oncology (2021)

BRAFV600 prevalence is highest in eGBM, PXA, aPXA, GG, aGG and lower in astroblastoma, DIA, SEGA, DNET, DA and PA. Our data provides the rationale for adjuvant clinical trials of BRAFi in V600-mutant glioma.

Keyphrases

systematic review
clinical trial
risk factors
early stage
meta analyses
wild type
randomized controlled trial
big data
phase ii